Market Research Logo

Global Depression Drugs Market 2015-2019

Global Depression Drugs Market 2015-2019

About depression drugs

According to the WHO, depression is a common mental disorder that contributes significantly to the global burden of disease. It affects people across communities worldwide. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration. Depression can be roughly categorized into six different types. An individual with severe depression can have suicidal thoughts and behaviors. According to a 2012 estimate by the WHO, about 3,000 suicides take place each day, resulting in more than a million deaths each year. Depression can be recurrent and can be severely debilitating. Patients with mild depression can be treated with medications, but in cases of moderate or severe depression, the patient needs both medication and professional psychotherapy in the form of counseling. According to a 2008 report by the WHO, depression affects men and women equally, but women are more likely to be affected by depression than men. According to the CDC, depression can lead to many adverse behaviors in an individual such as alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, in the US, one in every 10 individuals is affected by depression. According to the NIMH in the US, major depressive disorder is one of the most debilitating disorders in the US and affects about 14.80 million adults aged 18 years and above.

Technavio's analysts forecast the global depression drugs market to grow at a CAGR of 5.25% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global depression drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used for the treatment of depression. The global depression drugs market is segmented based on the mechanism of action of the drugs used to treat depression, as mentioned below:

  • Tricyclic antidepressants
  • Serotonin-norepinephrine reuptake inhibitors
  • Selective serotonin reuptake inhibitors
  • Monoamine oxidase inhibitors
  • Others


  • Technavio's report, Global Depression Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key regions
    • Americas
    • APAC
    • EMEA
    Key vendors
    • Actavis
    • Bristol-Myers Squibb
    • Eli Lilly
    • GlaxoSmithKline
    • Pfizer
    Other prominent vendors
    • Abbott Laboratories
    • Addex Therapeutics
    • Alkermes
    • AstraZeneca
    • Aurobindo Pharma
    • Avanir Pharmaceuticals
    • Cerecor
    • Chugai Pharmaceutical
    • Dart NeuroScience
    • Dr. Reddy's Laboratories
    • Edgemont Pharmaceuticals
    • E-Therapeutics
    • Euthymics
    • Evotec
    • F. Hoffmann-La Roche
    • Fabre Kramer
    • Gedeon Richter
    • H. Lundbeck
    • Intra-Cellular Therapies
    • Janssen Pharmaceuticals
    • Lupin
    • Luye Pharma
    • MSI Methylation Sciences
    • Naurex
    • Neuralstem
    • Novartis
    • Opko Health
    • Otsuka Pharmaceutical
    • Pierre Fabre
    • Shire
    • SK Biopharmaceuticals
    • Somerset Pharmaceuticals
    • Sun Pharmaceutical
    • Sunovion Pharmaceuticals
    • Suven
    • Takeda Pharmaceutical
    • Teva Pharmaceutical
    • Torrent Pharmaceuticals
    • Valeant Pharmaceuticals
    Market driver
    • Rise in patient population
    • For a full, detailed list, view our report
    Market challenge
    • Threat of expiry of patents
    • For a full, detailed list, view our report
    Market trend
    • Growing public awareness
    • For a full, detailed list, view our report
    Key questions answered in this report
    • What will the market size be in 2019 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?




    Press Release

    Technavio Announces the Publication of its Research Report – Global Depression Drugs Market 2015-2019

    Technavio recognizes the following companies as the key players in the global depression drugs market: Actavis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline and Pfizer

    Other Prominent Vendors in the market are: Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals and Valeant Pharmaceuticals

    Commenting on the report, an analyst from Technavio’s team said: “Growing public awareness about depression is expected to increase the acceptability of various drugs. The Anxiety and Depression Association of America, Mental Health America, Depression and Bipolar Support Alliance, Suicide Awareness, Voices of Education, and Freedom from Fear are non-profit organizations involved in spreading awareness of depression and its implications.”

    According to the report, WHO has described depression as one of the most disabling illnesses worldwide. In 2012, it was estimated that more than 18 million people suffered from depression in the US, affecting about 25% of women and 10% of men. According to the CDC, about one in every 10 individuals in the US suffers from depression. The prevalence rate of depression is very high because of factors such as genetic vulnerability, lack of proper diagnosis and treatment, and a high degree of association with other medical disorders such as diabetes, stroke, cardiovascular diseases, and psychiatric disorders.

    Further, the report states that the expiry of patents of major branded drugs is expected to lead to the erosion of their market share and a fall in revenue.

    Companies Mentioned

    Actavis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Valeant Pharmaceuticals

    • Executive Summary
    • List of Abbreviations
    • Scope of the Report
      • Market overview
      • Product offerings
    • Product Profiles
      • Celexa
        • Fetzima
        • Lexapro
        • Viibryd
        • Cymbalta
        • Prozac
        • Symbyax
        • Paxil
        • Wellbutrin
        • Abilify
        • Effexor
        • Pristiq
        • Zoloft
    • Market Research Methodology
      • Market Research Process
      • Research Methodology
        • Table Market Research Methodology
    • Introduction
    • Disorder Overview
      • Types of depression
        • Table NIMH classification of depression
        • Major depressive disorder
        • Persistent depressive disorder
        • Psychotic depression
        • Postpartum depression
        • Seasonal affective disorder
        • Bipolar disorder
      • Etiology
      • Epidemiology
        • Bipolar disorder among adults
          • Table Prevalence data for major depressive disorder among adults in US (2012)
        • Dysthymic disorder among adults
          • Table Prevalence data for dysthymic disorder among adults in US (2012)
        • Major depression among adults
          • Table 12-month prevalence data for major depressive disorder with severe impairment among adults in US (2012)
          • Table Prevalence data for major depressive disorder among adults in US (2012)
        • Major depression among adolescents
          • Table Prevalence data for major depression among adults in US (2012)
      • Treatment and management
        • Table WHO guidelines for management of depression
      • Economic burden
        • Table Economic burden of depression in US
        • Table Segmentation of costs associated with depression
        • Table Snapshot of economic burden of depression in US
    • Market Landscape
      • Market overview
      • Market size and forecast
        • Table Global depression drugs market 2014-2019 ($ millions)
      • Depression drugs market in US 2014-2019
        • Market size and forecast
          • Table Depression drugs market in US 2014-2019 ($ millions)
      • Five forces analysis
    • Market Segmentation by Mechanism of Action
      • Table Segmentation of global depression drugs market by mechanism of action
      • Table Segmentation of global depression drugs market by mechanism of action 2014
    • Geographical Segmentation
      • Segmentation of global depression drugs market by geography 2014
        • Table Segmentation of global depression drugs market by geography 2014
    • Pipeline Portfolio
      • Table Depression drugs: pipeline portfolio
      • Key information on late-stage pipeline molecules
        • Brexpiprazole
        • ALKS 5461
        • Cariprazine
        • TGFK07AD
    • Buying Criteria
    • Market Growth Drivers
    • Drivers and their Impact
    • Market Challenges
    • Impact of Drivers and Challenges
    • Market Trends
    • Trends and their Impact
    • Vendor Landscape
      • Competitive scenario
        • Key news
        • Mergers and acquisitions
      • Market share analysis 2014
        • Table Vendor ranking 2014
        • Competitive assessment of top drugs used for treating depression
          • Table YoY growth rate of major depression drugs 2010-2014 ($ millions)
          • Table Revenue comparison of top drugs used for treating depression in 2013 ($ millions)
        • Bristol-Myers Squibb
          • Table YoY global revenue of Abilify 2010-2014 ($ millions)
        • Eli Lilly
          • Table YoY global revenue of Cymbalta 2010-2014 ($ millions)
        • Pfizer
          • Table YoY global revenue of Pristiq 2010-2014 ($ millions)
          • Table YoY global revenue of Zoloft 2010-2014 ($ millions)
          • Table YoY global revenue of Effexor 2010-2014 ($ millions)
        • GlaxoSmithKline
          • Table YoY global revenue of Wellbutrin 2010-2013 ($ millions)
          • Table YoY revenue of Wellbutrin in US 2010-2013 ($ millions)
          • Table YoY global revenue of Paxil 2010-2014 ($ millions)
        • Actavis
      • Other and future prominent vendors
    • Key Vendor Analysis
      • Actavis
        • Key Facts
        • Business Overview
        • Business Segmentation
          • Table Actavis: Business Segmentation
        • Business Segmentation by Revenue 2012 and 2013
          • Table Actavis: Business Segmentation by Revenue 2012 and 2013 ($ million)
        • Geographical segmentation by Sales 2013
          • Table Actavis: Geographical segmentation by Sales 2013
        • Business Strategy
        • Recent Developments
        • SWOT Analysis
      • Bristol-Myers Squibb
        • Key Facts
        • Business Overview
        • Key Product Offerings
          • Table Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
        • Revenue by Geography
          • Table Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
        • Business Strategy
        • Key Information
        • SWOT Analysis
      • Eli Lilly
        • Key Facts
        • Business Overview
        • Business Segmentation by Revenue
          • Table Eli Lilly: Business Segmentation by Revenue 2013
          • Table Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
        • Sales by Geography
          • Table Eli Lilly: Sales by Geography 2013
        • Business Strategy
        • Key Information
        • SWOT Analysis
      • GlaxoSmithKline
        • Key facts
        • Business overview
        • Business segmentation by revenue 2014
          • Table GlaxoSmithKline: Business segmentation by revenue 2014
        • Business segmentation by revenue 2013 and 2014
          • Table GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
        • Geographical segmentation by revenue 2014
          • Table GlaxoSmithKline: Geographical segmentation by revenue 2014
        • Business strategy
        • Recent developments
        • SWOT analysis
      • Pfizer
        • Key facts
        • Business overview
        • Business segmentation by revenue 2014
          • Table Pfizer: Business segmentation by revenue 2014
        • Business segmentation by revenue 2013 and 2014
          • Table Pfizer: Business segmentation by revenue 2013 and 2014 ($ billion)
        • Geographical segmentation by revenue 2014
          • Table Pfizer: Geographical segmentation by revenue 2014
        • Business strategy
        • Key developments
        • SWOT analysis
    • Other Reports in this Series

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report